111 related articles for article (PubMed ID: 9816121)
1. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.
Izquierdo MA; Degen D; Raymond E; Caron D; Ortiz V; Banks P; Von Hoff DD
Clin Cancer Res; 1996 Oct; 2(10):1713-6. PubMed ID: 9816121
[TBL] [Abstract][Full Text] [Related]
2. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
[TBL] [Abstract][Full Text] [Related]
3. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
Vadhan-Raj S
Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
Anderson JE; Appelbaum FR
Curr Opin Hematol; 1994 May; 1(3):203-9. PubMed ID: 9371283
[TBL] [Abstract][Full Text] [Related]
5. The effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function.
Buescher ES; McIlheran SM; Banks SM; Vadhan-Raj S
Exp Hematol; 1993 Oct; 21(11):1467-72. PubMed ID: 8405227
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines.
Foulke RS; Marshall MH; Trotta PP; Von Hoff DD
Cancer Res; 1990 Oct; 50(19):6264-7. PubMed ID: 2205378
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
Schwartz GN; Kammula U; Warren MK; Park MK; Yan XY; Marincola FM; Gress RE
Stem Cells; 2000; 18(5):331-42. PubMed ID: 11007917
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients.
Ross AA; Loudovaris M; Hazelton B; Weaver CH; Schwartzberg L; Bender JG
Exp Hematol; 1995 Dec; 23(14):1478-83. PubMed ID: 8542934
[TBL] [Abstract][Full Text] [Related]
10. In vitro growth effects of colony-stimulating factors in ovarian cancer.
Connor JP; Squatrito RC; Terrell KL; Antisdel BJ; Buller RE
Gynecol Oncol; 1994 Mar; 52(3):347-52. PubMed ID: 7512521
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
12. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
13. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
14. Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes.
Suzuki H; Katayama N; Ikuta Y; Mukai K; Fujieda A; Mitani H; Araki H; Miyashita H; Hoshino N; Nishikawa H; Nishii K; Minami N; Shiku H
Am J Hematol; 2004 Apr; 75(4):179-89. PubMed ID: 15054806
[TBL] [Abstract][Full Text] [Related]
15. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2.
Uemura Y; Kobayashi M; Nakata H; Kubota T; Saito T; Bandobashi K; Taguchi H
Oncol Rep; 2007 Apr; 17(4):955-61. PubMed ID: 17342342
[TBL] [Abstract][Full Text] [Related]
16. Effects of GM-CSF, IL-3, and GM-CSF/IL-3 fusion protein on apoptosis of human myeloid leukemic cell line Tf-1 induced by irradiation.
Yang SR; Wen L; Lu YQ; Gong QY; Yu R; Yao MH
Acta Pharmacol Sin; 2004 Jan; 25(1):68-75. PubMed ID: 14704125
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo.
Gutschalk CM; Herold-Mende CC; Fusenig NE; Mueller MM
Cancer Res; 2006 Aug; 66(16):8026-36. PubMed ID: 16912178
[TBL] [Abstract][Full Text] [Related]
18. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
[TBL] [Abstract][Full Text] [Related]
19. The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
Ripley D; Tang XM; Ma C; Chegini N
Gynecol Oncol; 2001 May; 81(2):301-9. PubMed ID: 11330966
[TBL] [Abstract][Full Text] [Related]
20. Hybrid cytokines as hematopoietic growth factors.
Williams DE; Park LS; Broxmeyer HE; Lu L
Int J Cell Cloning; 1991 Nov; 9(6):542-7. PubMed ID: 1770228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
